Starpharma Holdings (ASX: SPL) is focused on the development of dendrimer nanotechnology for pharmaceutical, drug delivery and other applications. Products based on Starpharma’s dendrimer technology are already on the market as diagnostic elements and laboratory reagents through licence agreements.
Orbis Investment Management ups stake in Starpharma to 8.7%
Substantial shareholder Orbis Investment Management has significantly increased its investment in Australian-listed biotechnology company, Starpharma Holdings (ASX:SPL, OTCQX:SPHRY).
Orbis acquired approximately 2.565 million shares on-market at an average price of A$0.64 per share between 21 May to 16 June. The share buy takes Orbis' interest to 20.8 million shares, or 8.7% of Starpharma.
Starpharma is a market leader in the development of dendrimer products for pharmaceutical, life-science and other applications. Its partnerships include Durex, Lilly, Elanco, Stiefel (now GlaxoSmithKline), Siemens and Merck.
Commencement of royalty revenue is estimated to commence in CY11 with VivaGel coated condoms.









